Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia

JAMA Psychiatry

Volumn 74, Issue 7, 2017, Pages 686-693

  Tiihonen, Jari ^a,b   Mittendorfer Rutz, Ellenor ^a   Majak, Maila ^c   Mehtälä, Juha ^c   Hoti, Fabian ^c   Jedenius, Erik ^d   Enkusson, Dana ^d   Leval, Amy ^d   Sermon, Jan ^e   Tanskanen, Antti ^a,b,f   Taipale, Heidi ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c EPID Research Oy   (Finland)

^d Janssen Cilag AB   (Sweden)

^e Janssen Cilag EMEA Belgium   (Belgium)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL; DELAYED RELEASE FORMULATION;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SELECTION BIAS; SUICIDE ATTEMPT; SWEDEN; DELAYED RELEASE FORMULATION; MIDDLE AGED; OUTCOME ASSESSMENT; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; THERAPEUTIC USE; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT READMISSION; SCHIZOPHRENIA; SECONDARY PREVENTION; SWEDEN; TREATMENT FAILURE; YOUNG ADULT;

EID: 85020619657     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.1322     Document Type: Article

References (25)

1. Davis JM, Chen N, Glick ID. Ameta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564
2. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: ameta-analysis. Lancet. 2009;373(9657):31-41
3. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.Lancet. 2013;382(9896):951-962
4. Hofer A, Hummer M, Huber R, Kurz M, Walch T, FleischhackerWW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000; 20(6):699-702
5. Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71(2):103-108
6. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224
7. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627
8. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.AmJ Psychiatry. 2011;168(6):603-609
9. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5): 476-483
10. Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173(6):600-606
11. Crump C, WinklebyMA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324-333
12. Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, Häkkinen U, Isohanni M, Hakko H. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res. 2013;150(1):274-280
13. Hayes RD, Downs J, Chang CK, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015;41(3):644-655
14. Vanasse A, Blais L, Courteau J, et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand. 2016;134(5):374-384
15. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656-663
16. WHOCollaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System: structure and principles. https://www.whocc.no/atc/structure-and-principles/.Updated March 25, 2011. Accessed February 1, 2017
17. Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367 (21):2006-2014
18. Chang Z, Lichtenstein P, Långström N, Larsson H, Fazel S. Association between prescription of major psychotropic medications and violent reoffending after prison release. JAMA. 2016;316 (17):1798-1807
19. Tiihonen J. Real-world effectiveness of antipsychotics. Acta Psychiatr Scand. 2016;134(5): 371-373
20. Alphs L, Nasrallah HA, Bossie CA, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmacol. 2016;31(4): 202-209
21. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: ameta-analysis of randomized trials. Schizophr Bull. 2014;40(1): 192-213
22. Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C.Does formulation matter? a systematic review and meta-analysis of oral versus long-acting antipsychotic studies [published online November 17, 2016].Schizophr Res. 2016;S0920-9964(16)30503-5.doi:10.1016/j.schres.2016.11.010
23. Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72 (8):822-829
24. Rabinowitz J, Levine SZ, Barkai O, Davidov O.Dropout rates in randomized clinical trials of antipsychotics: ameta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009; 35(4):775-788
25. Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S. Agreement between PRE2DUP register data modelingmethod and comprehensive drug use interview among older persons. Clin Epidemiol. 2016;8:363-371